Skip to main content

Warts

6
Pipeline Programs
7
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
2
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 7 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Orion
OrionUK - Cambridge
1 program
1
Imiquimod 5% creamPhase 4
Orion Pharma
Orion PharmaUK - Reading
1 program
1
Imiquimod 5% creamPhase 41 trial
Active Trials
NCT00761371Completed52Est. Feb 2004
MSD
MSDIreland - Ballydine
1 program
1
Human Papillomavirus 9-valent Vaccine, RecombinantPhase 2/3Vaccine1 trial
Active Trials
NCT05625633Recruiting120Est. Dec 2026
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Human Papillomavirus 9-valent Vaccine, RecombinantPhase 2/3Vaccine
Nielsen BioSciences
Nielsen BioSciencesCA - San Diego
2 programs
2
CANDINPhase 21 trial
Candida albicans Skin Test AntigenPhase 21 trial
Active Trials
NCT02393417Completed243Est. Mar 2018
NCT01757392Completed39Est. Dec 2014
Pulse Biosciences
Pulse BiosciencesCA - Hayward
2 programs
CellFX DeviceN/A1 trial
CellFX System DeviceN/A1 trial
Active Trials
NCT04554394Completed62Est. Dec 2020
NCT04738734Completed150Est. Sep 2022
Combined Therapeutics
1 program
CRYOTHERAPYN/A1 trial
Active Trials
NCT05712811Completed60Est. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Orion PharmaImiquimod 5% cream
MSDHuman Papillomavirus 9-valent Vaccine, Recombinant
Nielsen BioSciencesCANDIN
Nielsen BioSciencesCandida albicans Skin Test Antigen
Combined TherapeuticsCRYOTHERAPY
Pulse BiosciencesCellFX System Device
Pulse BiosciencesCellFX Device

Clinical Trials (7)

Total enrollment: 726 patients across 7 trials

NCT00761371Orion PharmaImiquimod 5% cream

Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients

Start: Aug 2002Est. completion: Feb 200452 patients
Phase 4Completed
NCT05625633MSDHuman Papillomavirus 9-valent Vaccine, Recombinant

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Start: Mar 2024Est. completion: Dec 2026120 patients
Phase 2/3Recruiting
NCT02393417Nielsen BioSciencesCANDIN

Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

Start: Mar 2015Est. completion: Mar 2018243 patients
Phase 2Completed
NCT01757392Nielsen BioSciencesCandida albicans Skin Test Antigen

Candin Safety & Efficacy Study for the Treatment of Warts

Start: Sep 2012Est. completion: Dec 201439 patients
Phase 2Completed
NCT05712811Combined TherapeuticsCRYOTHERAPY

Comparison of Cryotherapy and Peeling Agent in the Treatment of Common Warts

Start: Jun 2022Est. completion: Nov 202260 patients
N/ACompleted
NCT04738734Pulse BiosciencesCellFX System Device

CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts

Start: Feb 2021Est. completion: Sep 2022150 patients
N/ACompleted
NCT04554394Pulse BiosciencesCellFX Device

CellFX System for the Treatment of Cutaneous Non-Genital Warts

Start: Jul 2019Est. completion: Dec 202062 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 726 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.